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Abstract
Background: MicroRNAs (miRNAs) in circulation have emerged as promising biomarkers. In this study, we aimed to
identify a circulating miRNA signature for osteoarthritis (OA) patients and in combination with bioinformatics analysis
to evaluate the utility of selected differentially expressed miRNAs in the serum as potential OA biomarkers.
Methods: Serum samples were collected from 12 primary OA patients, and 12 healthy individuals were screened using
the Agilent Human miRNA Microarray platform interrogating 2549 miRNAs. Receiver Operating Characteristic (ROC)
curves were constructed to evaluate the diagnostic performance of the deregulated miRNAs. Expression levels of
selected miRNAs were validated by quantitative real-time PCR (qRT-PCR) in all serum and in articular cartilage samples
from OA patients (n = 12) and healthy individuals (n = 7). Bioinformatics analysis was used to investigate the involved
pathways and target genes for the above miRNAs.
Results: We identified 279 differentially expressed miRNAs in the serum of OA patients compared to controls. Two
hundred and five miRNAs (73.5%) were upregulated and 74 (26.5%) downregulated. ROC analysis revealed that 77
miRNAs had area under the curve (AUC) > 0.8 and p < 0.05. Bioinformatics analysis in the 77 miRNAs revealed that their
target genes were involved in multiple signaling pathways associated with OA, among which FoxO, mTOR, Wnt, pI3K/akt,
TGF-β signaling pathways, ECM-receptor interaction, and fatty acid biosynthesis. qRT-PCR validation in seven selected out
of the 77 miRNAs revealed 3 significantly downregulated miRNAs (hsa-miR-33b-3p, hsa-miR-671-3p, and hsa-miR-140-3p)
in the serum of OA patients, which were in silico predicted to be enriched in pathways involved in metabolic processes.
Target-gene analysis of hsa-miR-140-3p, hsa-miR-33b-3p, and hsa-miR-671-3p revealed that InsR and IGFR1 were common
targets of all three miRNAs, highlighting their involvement in regulation of metabolic processes that contribute to OA
pathology. Hsa-miR-140-3p and hsa-miR-671-3p expression levels were consistently downregulated in articular cartilage of
OA patients compared to healthy individuals.
Conclusions: A serum miRNA signature was established for the first time using high density resolution miR-arrays in OA
patients. We identified a three-miRNA signature, hsa-miR-140-3p, hsa-miR-671-3p, and hsa-miR-33b-3p, in the serum of
OA patients, predicted to regulate metabolic processes, which could serve as a potential biomarker for the evaluation of
OA risk and progression.
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Background
Osteoarthritis (OA) is the most common chronic degen-
erative joint disease and a leading cause of pain and
disability. Its prevalence is steadily increasing and is ex-
pected to be the greatest cause of disability by 2030 [1].
OA is defined as a heterogeneous disease consisting of a
group of distinct joint disorders with common biological,
morphological, and clinical outcomes [2]. To date, several
risk factors, including aging, obesity, sex, joint injury, and
heredity have been implicated in disease development and
progression [3, 4]. Recently, an association has been sug-
gested between OA and metabolic syndrome or metabolic
risk factors, as hypertension, overweight, dyslipidemia, and
insulin resistance, and a new OA subtype, metabolic OA,
has been introduced [5–7]. As the above metabolic factors
can be modified, it becomes evident that understanding
the molecular mechanisms which are involved in OA
pathogenesis is essential for the discovery of OA personal-
ized therapies. However, until now, despite the significant
burden that OA imposes in patients and in healthcare sys-
tems [8], there is absence of effective non-arthroplasty
treatment options for disease management. One major
challenge for the development of effective therapy for OA
is the detection of the disease at an early stage. To date,
the standard method for disease diagnosis and severity is
the radiograph, which appears to be limited to detection in
late disease stages and has weakness in monitoring disease
progression [9]. Therefore, the identification of non-
invasive and sensitive serum biomarkers will assist OA
diagnosis, prognosis, and early treatment before the onset
of radiographic findings.
MicroRNAs (miRNAs) are a novel group of universally
present small non-coding RNAs, approximately 22–28
nucleotides in length, which regulate gene expression at
the post-transcriptional level through mRNA degradation
or translational repression. Each miRNA can regulate a
large number of genes by binding mainly to the 3′UTR of
mRNA targets [10]. Recent studies have implicated miR-
NAs as promising clinical biomarkers in various diseases
including cancer, diabetes, and cardiovascular disease
[11–14]. MiRNAs have also been associated with pro-
cesses involved in OA pathogenesis, such as cartilage
homeostasis, extracellular matrix regulation, endochon-
dral ossification, bone metabolism, apoptosis, autophagy,
inflammation, and lipid metabolism [15, 16]. Our group
was among the pioneers to suggest the involvement of
miRNAs in OA pathogenesis by demonstrating the differ-
ential expression of 16 miRNAs in OA compared to
healthy articular cartilage [17].
Recently, the use of microarrays for the global
characterization of miRNA expression profiling is becom-
ing a strong research tool that provides useful information
on the pathogenesis of many diseases [12]. Several micro-
RNA profiling studies have been performed in different
OA tissues and have led to the identification of numerous
differentially expressed miRNAs between OA joint tissues
and controls [17, 18]. However, in the majority of these
studies, the number of miRNAs tested was limited, ran-
ging from 157 to 723 miRNAs, compared to 2588 mature
miRs recently released from the Sanger Institute and
University of Manchester miRbase (release June 2014)
allowing for many more miRNAs to be identified [19].
Moreover, miRNAs have been discovered in circulation,
however, the origin and the biological functions of the cir-
culating miRNAs in a disease remain poorly understood.
Evidence suggests that circulating miRNAs could be trans-
ferred in the circulation through microvesicles, exosomes,
Ago protein complexes, or HDL and that they are either
byproducts of the cellular content or are mediating the
inter-cellular signaling reflecting the pathophysiological
state of the cell [20–23]. Alterations in their expression
levels in abnormal conditions along with their stability in
circulation and surprisingly long half-life of approximately
5 days in plasma [24] have implicated them as attractive
molecules for disease prognosis and/or progression [11].
Circulating miRNAs have been demonstrated as important
biomarkers in many diseases, as diabetes type II [25] meta-
bolic syndrome [26] Alzheimer’s, hypertension, osteopor-
osis, Parkinson’s disease, and cancer [12]. Recently, a
limited number of studies highlighted the role of circulat-
ing miRNAs as potential biomarkers for assessment of
prognosis and/or progression in osteoarthritis [23, 27, 28].
However, a systematic analysis of serum miRNA profiling
in osteoarthritis has not yet been performed.
In the present study, we performed miRNA profiling
using high-density miRNA-arrays in serum of OA patients
and in combination with bioinformatics analysis evaluated
the utility of selected differentially expressed miRNAs as
potential OA biomarkers.
Methods
Patient samples
Serum samples were collected from 12 patients with pri-
mary OA (9 females, 3 males, ages 69.83 ± 4.83 years)
undergoing total knee replacement surgery at the
Orthopaedics Department of the University Hospital of
Larissa. Radiographs were obtained before surgery and
were graded using the Kellgren-Lawrence system accord-
ing to the following criteria: grade 1 (doubtful narrowing
of joint space and possible osteophytes), grade 2 (definite
osteophytes and possible narrowing of joint space), grade
3 (moderate multiple osteophytes, definite narrowing of
joint space and some sclerosis, and possible deformity of
bone ends), and grade 4 (large osteophytes, marked nar-
rowing of joint space, severe sclerosis, and definite de-
formity of bone ends). All OA patients had a Kellgren-
Lawrence grade ≥ 3. The assessment of the radiographs by
two independent expert observers was blinded. Patients
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with rheumatoid arthritis and other autoimmune disease as
well as chondrodysplasias, infection-induced OA, and post-
traumatic OA were excluded from the study. As controls,
serum samples were obtained from 12 healthy individuals
(6 females, 6 males, ages 64,25 ± 5,04 years) undergoing
knee fracture repair surgery, with no history of joint dis-
ease, who did not show clinical manifestations compatible
with OA when specifically explored by radiography. The
clinical characteristics of OA patients and the control
cohort are shown in Table 1. All individuals who partici-
pated in the study were of Greek origin. The study protocol
conformed to the ethical guidelines of the 1975 Declaration
of Helsinki as reflected in a priori approval by the local
ethical committee of the University Hospital of Larissa.
Articular cartilage samples (n = 12) were collected from
femoral condyles and tibial plateaus of the same OA
patients undergoing total knee replacement surgery.
Normal articular cartilage was obtained from small free
cartilaginous fragments of 7 out of the 12 healthy individ-
uals undergoing knee fracture repair surgery. Signed
informed consent was obtained from all OA and healthy
individuals prior to surgery and/or blood drawing.
RNA extraction and microRNA expression profiling by
microarray in serum of OA patients and healthy
individuals
Total RNA was extracted from serum samples using the
RiboEXTMLS kit (GeneAll, Seoul, Korea). RNA quantity
and quality were evaluated using a spectrophotometer
(NanoDrop® ND-1000 UV-Vis, Nanogen Inc.). Total RNA
samples were spiked using the microRNA Spike-In Kit
(Agilent Technologies Inc., Santa Clara, CA, USA) to as-
sess the labeling and hybridization efficiencies. Labeling
and hybridization were performed using the miRNA
complete Labeling and Hybridization Kit (Agilent
Technologies Inc., Santa Clara, CA, USA) according to
manufacturer’s instructions. Samples were hybridized to
the SurePrint G3 Human miRNA, 8X60K platform (miR-
Base release 21.0, Agilent Technologies Inc., Santa Clara,
CA, USA) containing probes for the detection of 2549 hu-
man miRNAs. Images were scanned using Agilent
Microarray Scanner (G2565CA) controlled by Agilent
Scan Control 7.0 software. The signal after background
subtraction was exported directly into Agilent Feature Ex-
traction Software version 4.0.1.21 (Agilent Technologies
Inc., Santa Clara, CA, USA). Normalization was per-
formed using quantile algorithm. MicroRNAs were con-
sidered as differentially expressed (DE) if they obtained a
p value < 0.05 and a false discovery rate (FDR) ≤ 0.05.
ROC analysis
Receiver Operating Characteristic curves (ROC) analysis
was performed using the MATLAB® simulation environ-
ment and was used to calculate the area under the curve
(AUC) value along with standard error and 95% confi-
dence intervals. ROC curves were considered significant
with AUC value > 0.8 and a p value < 0.05.
Quantitative real-time polymerase chain reaction (qRT-
PCR) validation of selected miRNAs in serum of OA and
healthy individuals
The expression levels of 7 selected miRNAs screened
with miRNA microarrays, as mature hsa-miR-33b-3p,
hsa-miR-4284, hsa-miR-663a, hsa-miR-150-5p, hsa-miR-
1233-3p, hsa-miR-140-3p, and hsa-miR-671-3p, were
evaluated in serum samples from 12 OA patients and 12
healthy controls. More specifically, reverse transcription
was carried out with 100 ng of total RNA using MiScript
II Reverse Transcription Kit (QIAGEN Inc., Valencia,
CA, USA). The relative quantification of selected differ-
entially expressed miRNAs was performed by qRT-PCR
reaction with the miScript SYBR® Green PCR Kit
(QIAGEN Inc., Valencia, CA, USA) and MiScript Primer
Assays (QIAGEN Inc., Valencia, CA, USA), using an
ABI 7300 Real-Time PCR System (Applied Biosystems,
Foster City, CA, USA). Reactions were performed in du-
plicate. The relative expression levels were calculated
Table 1 Clinical characteristics of OA patients and healthy
controls
Sample Group Sex Age BMI K-L score
01OA OA F 68 29 4
02OA OA M 69 29 4
03OA OA F 64 33.3 4
04OA OA F 77 33 3
05OA OA F 70 28 3
06OA OA M 71 28.5 4
07OA OA M 63 34.59 3
08OA OA F 66 27.6 4
09OA OA F 77 28 3
10OA OA F 66 32.4 4
11OA OA F 76 30.5 4
12OA OA F 71 39.1 4
1A Control F 65 23.79 0
2A Control M 75 23.5 0
3A Control F 63 22 0
4A Control M 68 29.74 0
5A Control M 66 29.38 0
6A Control F 60 23 0
7A Control F 68 28 0
8A Control M 64 29 0
9A Control M 63 27 0
10A Control F 54 30 0
11A Control F 63 21.6 0
12A Control F 62 20.2 0
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using the 2−ΔΔCT method. Normalized gene expression
values for each gene were generated based on cycle
threshold (CT) values for each of the genes. Hsa-miR-
25-1 was used as endogenous control, as it exhibited
minimum variance between the controls and patients in
miRNA microarray analysis. Also, its stability was con-
firmed using the NormFinder software [29].
Primary cultures of OA and normal and articular
chondrocytes
Articular cartilage was dissected and subjected to diges-
tion with 1 mg/ml pronase (Roche Applied Science,
Mannheim, Germany) for 30 min and then the sample
was centrifuged and the pellet was subjected to digestion
with 1 mg/ml collagenase P (Roche Applied Science,
Mannheim, Germany) for 3 h at 37 °C. Chondrocytes
were counted and checked for viability using trypan blue
staining. More than 95% of the cells were viable after
isolation. Chondrocytes were cultured with Dulbecco’s
modified Eagles medium/Ham’s F-12 (DMEM/F-12)
(GIBCO, BRL, UK) plus 5% fetal bovine serum (FBS,
GIBCO, BRL, UK) and 100 U/ml penicillin-
streptomycin, and were incubated at 37 °C under a hu-
midified 5% CO2 atmosphere until reaching confluence.
Chondrocytes were kept in culture for one passage,
while types I and II collagen ratios were evaluated in all
samples to exclude dedifferentiation events.
RNA extraction and quantification of miRNA expression
from OA and healthy articular cartilage
Total cellular RNA was extracted from cultured chondro-
cytes using Trizol reagent (Invitrogen, Life Technologies,
Paisley, UK). RNA quantity and quality was evaluated
using a spectrophotometer (NanoDrop® ND-1000 UV-Vis,
Nanogen Inc.). Reverse transcription was conducted using
the SuperScript III Reverse Transcriptase kit (Invitrogen/
Thermo Fisher Scientific Inc., USA), using primers spe-
cific for hsa-miR-33b-3p, has-miR-4284, hsa-miR-663a,
hsa-miR-150-5p, hsa-miR-1233-3p, hsa-miR-140-3p, hsa-
miR-671-3p, and U6 small nuclear RNA (RNU6B) stem-
loop RT primer to generate the cDNA as previously de-
scribed [30]. MiRNA expression was verified by qRT-PCR.
Reactions were done in duplicate. The reactions were per-
formed using Power SYBR Green PCR Master Mix (Ap-
plied Biosystems) and specific primers (forward and
reverse) for each miRNA. For the quantification of the
relative expression of each miRNA, the threshold cycle
(Ct) values were normalized against the endogenous refer-
ence U6. The 2−ΔΔCT method was used [30].
Statistical analyses and data analyses
Multiparameter analyses were performed with the
MATLAB ® simulation environment (The Mathworks Inc.,
Natick, MA, USA). In particular, data pre-processing was
performed in Microsoft Excel ® and data processing was
performed within the Matlab® v.7.6.0 (The MathWorks
Inc. Natick, MA, USA) computing environment, using the
Bioinformatics Toolbox. For background correction, the
well-performing multiplicative background correction
(MBC) approach was followed [31]. In terms of filtering,
as low signal intensity measurements are less reliable in
terms of the impact of noise on them, than high gene ex-
pression measurements, an intensity-dependent filtering
[32, 33] with an absolute threshold value of 10 was used,
in order to exclude low quality features. A threshold of 1
was set as a cut-off value, meaning that spot intensity
should be at least the same as that of the background. The
quantile normalization method was used for further pro-
cessing [34]. In order to identify potentially differentially
expressed (DE) genes between samples and among genes
of the same experiment a two-tailed Student’s t test was
used to test the mean differences between the two groups.
Genes that received a p < 0.05 were considered as DE. Fur-
ther on, the false discovery rate (FDR has been calculated
as described previously [35–37]. There was a FDR of
0.007% for p < 0.05.
Continuous variables are expressed as median ± stand-
ard deviation unless indicated differently. k-means and
hierarchical clustering (HCL) analyses of microRNA ex-
pression were performed using all differentially
expressed (DE) miRNAs with Euclidian distance.
RNA target prediction for selected miRNAs was per-
formed with TargetScan v. 7.0 [38] and DIANA Tools, a
collection of web-tools for miRNA functional annotation
analysis [39]. Functional annotation was performed with
the Webgestalt web-tool [40] and DIANA tools. Further-
more, KEGG pathway enrichment analysis was conducted
for the target genes using the Database for Annotation,
Visualization and Integrated Discovery (DAVID) online
tools [41] with the cut-off criterion of p < 0.05.
Venn diagrams were generated with the Venn Diagram
Calculator from the Bioinformatics, Evolutionary
Genomics Group of the University of Gent.
Results
MicroRNA microarray profiling in serum of OA patients
and healthy individuals
Among the 2549 miRNAs tested using the Agilent 8 ×
60 K miRNA-array platform, a total of 279 miRNAs were
found to be differentially expressed (205 upregulated and
74 downregulated) (FDR < 0.008, p < 0.05) in the serum of
OA patients compared to healthy individuals (Fig. 1a, b).
Classification methods were used in order to detect pat-
terns in gene expression. Unsupervised two-way hierarch-
ical clustering (HCL) with Euclidian distance and k-means
analyses could not discriminate accurately between OA
and normal serum samples (data not shown).
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Diagnostic value of miRNAs in serum
Receiver Operating Characteristic (ROC) curves were
established to evaluate the diagnostic value of deregulated
miRNAs in discriminating between OA patients and
healthy individuals. ROC analysis revealed that 77 miRNAs
had an area under the curve (AUC) > 0.8 at a p < 0.05 sig-
nificance level, that could thus separate OA from control
samples. ROC analysis results are summarized in
Additional file 1: Table S1. Among the 77 miRNAs, 7 miR-
NAs, hsa-miR-33b-3p, hsa-miR-4284, hsa-miR-663a, hsa-
miR-150-5p, hsa-miR-1233-3p, hsa-miR-671-3p, and hsa-
miR-140-3p, were selected for further validation based on
the fact that they were in the top 20 up- or downregulated
miRNAs as found in microarray microRNA expression
profiling presented in Fig. 1a, b. More specifically, miR-
33b-3p and miR-4284 were among the top upregulated,
and miR-663a, miR150-5p, miR-1233-3p, miR-671-3p, and
miR-140-3p were downregulated.
ROC curve analysis of the seven selected miRNAs is
presented in Fig. 2.
Validation of selected miRNAs expression in serum of OA
and healthy individuals by qRT-PCR
We verified by qRT-PCR the expression levels of the seven
selected miRNAs (hsa-miR-33b-3p, hsa-miR-4284, hsa-
miR-663a, hsa-miR-150-5p, hsa-miR-1233-3p, hsa-miR-
140-3p, and hsa-miR-671-3p) in all serum samples.
Among these seven miRNAs, 3 miRNAs, hsa-miR-33b-3p,
hsa-miR-671-3p, and hsa-miR-140-3p, were found signifi-
cantly downregulated in OA serum samples compared to
controls (p < 0.05) (Fig. 3a).
Fig. 1 a Graphical representation of the downregulated differentially expressed (DE) miRNAs between OA patients and healthy individuals. Fold
change has been estimated by calculating the log2 of the OA over control ratio. b Graphical representation of the upregulated differentially
expressed (DE) miRNAs between OA patients and healthy individuals. Fold change has been estimated by calculating the log2 of the OA over
control ratio
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Moreover, we found that hsa-miR-33b-3p and hsa-miR-
4284 expression levels coincided between microarray ana-
lysis and qRT-PCR, exhibiting decreased expression in
serum of OA samples compared to controls. Hsa-miR-
663a, hsa-miR-150-5p, hsa-miR-1233-3p, hsa-miR-140-3p,
and hsa-miR-671-3p, which were marginally over-
expressed in microarray analysis, appeared to be downreg-
ulated with qRT-PCR. This discrepancy might be due to
technical limitations of the microarray methodology
(Fig. 3b).
Pathway analysis and target gene prediction
Pathway enrichment analysis of the 77 miRNAs that were
found significant in ROC analysis revealed that these DE
miRNAs are potentially involved in pathways associated
with OA pathogenesis, as among others, thyroid hormone,
FoxO, mTOR, sphingolipoid, MAPK, PI3K-Akt, Wnt,
ErbB, estrogen and TGF-beta signaling pathways, ECM-
receptor interaction, and fatty acid biosynthesis. Anno-
tated pathways are summarized in Table 2.
Furthermore, by considering the qRT-PCR data, we fo-
cused on predicted target genes, by TargetScan, of the
three miRNAs (hsa-miR-140-3p, hsa-miR-33b-3p, and
hsa-miR-671-3p) that were found downregulated in the
serum of OA patients. It appeared (Fig. 4) that these genes
are predicted targets of two or more of the three miRNAs.
More specifically, 28 genes were co-targeted by at least 2
miRNAs. Among these, INSR and IGF1R were targeted by
all three miRNAs, while ADCY7, VANGL1, WNT5A,
PPP3R2, TGFBR1, FZD4, BRAF, and CREB5 were co-
targeted by hsa-miR-140-3p, and hsa-miR-671-3p,
RPTOR, CDKN1A, PRKCB, ADCYA1, PDPK1, MAPK1,
ADCY2, TCS1, Kras, CBL, CHRM3, SGL1, CREB1,
KCNN3, PRKC1, PPP2R5E, and KCNJ11 were co-targeted
by hsa-miR-33b-3p, and hsa-miR-140-3p and KCNN1
were co-targeted by hsa-miR-671-3p and hsa-miR-33b-3p.
Pathway enrichment analysis (Additional file 2: Table
S2) revealed that the target genes of hsa-miR-140-3p,
hsa-miR-33b-3p,and hsa-miR-671-3p are potentially in-
volved in 48 common signaling pathways, including
Fig. 2 ROC analysis of miRNAs separating OA from control samples. Seven miRNAs were selected for further analysis and verification. Hsa-miR-
1233-3p (a), hsa-miR-140-3p (b), hsa-miR-150-5p (c), hsa-miR-33-3p (d), hsa-miR-4284 (e), hsa-miR-663a (f), and hsa-miR-671-3p (g) manifested an
area under the curve (AUC) value > 0.8 (AUC > 0.8) and p < 0.01
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thyroid hormone synthesis, FoxO signaling pathway, in-
sulin secretion, chemokine signaling pathway, MAPK
signaling pathway, PI3K-Akt signaling pathway, estrogen
signaling pathway, regulation of lipolysis in adipocytes,
glucagon signaling pathway, and calcium signaling path-
way, whereas 40 common pathways were predicted com-
mon between miR-140-3p and miR-33b-3p, such as
mTOR signaling pathway, osteoclast differentiation, Ras
signaling pathway, type II diabetes mellitus, adipocyto-
kine signaling pathway, thyroid hormone signaling path-
way, insulin signaling pathway, insulin resistance,
sphingolipid signaling pathway, sphingolipid metabolism,
and ErbB signaling pathway. Furthemore, five pathways
were predicted between miR-140-3p and miR-671-3p,
including Wnt signaling pathway, endocrine and other
factor-regulated, and calcium reabsorption (Fig. 5).
Disease annotation
Based on the previous list of the revealed miRNAs, we fur-
ther investigated their association with known diseases. It
appeared that the miRNAs we identified participate in
arthritis, joint diseases, and rheumatic disease. Interest-
ingly, our identified miRNAs included hsa-miR-140-3p,
which participated in arthritis, joint diseases, and rheuma-
toid disease. On average, hsa-miR-140-3p was found to be
downregulated in all OA samples. The results of the
Disease Annotation are summarized in Table 3.
miRNA expression in OA and healthy articular cartilage
samples
We next evaluated by qRT-PCR the expression levels of
the 7 selected miRNAs (hsa-miR-33b-3p, hsa-miR-4284,
hsa-miR-663a, hsa-miR-150-5p, hsa-miR-1233-3p, hsa-
miR-140-3p and hsa-miR-671-3p) in 12 OA and 7 healthy
articular cartilage samples. The expression levels of hsa-
miR-140-3p, hsa-miR-150-5p, and hsa-miR-671-3p were
significantly decreased in OA articular cartilage compared
to healthy cartilage (p < 0.05) (Fig. 6). No significant differ-
ences were observed for hsa-miR-33-3p, hsa-miR-4284,
hsa-miR-663a, and hsa-miR-1233-3p expression levels be-
tween OA and healthy articular cartilage.
Fig. 3 a Diagram of relative miRNA expression levels by qRT-PCR in the serum of healthy individuals (n = 12) and OA patients (n = 12). MiR-25-1
was used for normalization of the real-time PCR data. *p < 0.05 as measured using an unpaired Students’s t test. Hsa-miR-140-3p, hsa-miR-671-3p,
and hsa-miR-33b-3p were significantly downregulated in serum samples of OA patients compared to healthy individuals. b Comparative diagram
of miRNA expression levels between miRNA microarray analysis and as validated by qRT-PCR in serum samples of OA patients (n = 12)
and healthy individuals (n = 12). The expression levels of hsa-miR-33b-3p and hsa-miR-4284 coincided between the two methodologies,
while hsa-miR-1233-3p, hsa-miR-140-3p, hsa-miR-150-5p, hsa-miR-663a, and hsa-miR-671-3p were marginally overexpressed in microarray
analysis and appeared to be down-regulated with qRT-PCR
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Table 2 Summary of 77 miRNAs that were found significant in ROC analysis in common annotated pathways
KEGG pathway p value #genes #miRNAs
Proteoglycans in cancer 3.10E-11 156 64
Morphine addiction 1.07E-05 68 54
Circadian entrainment 1.07E-05 78 55
Adherens junction 3.37E-05 62 57
Phosphatidylinositol signaling system 6.91E-05 61 55
Axon guidance 6.91E-05 100 56
Glutamatergic synapse 6.91E-05 92 56
Thyroid hormone signaling pathway 0.000101627 90 62
Ras signaling pathway 0.000108175 167 66
Fatty acid biosynthesis 0.000111286 9 17
Retrograde endocannabinoid signaling 0.000113352 78 52
Rap1 signaling pathway 0.000113352 157 64
Dopaminergic synapse 0.000186561 101 57
Pathways in cancer 0.000227243 284 69
Hippo signaling pathway 0.000362414 111 62
N-Glycan biosynthesis 0.000416091 35 41
Inflammatory mediator regulation of
TRP channels
0.000430502 74 48
GABAergic synapse 0.000725271 68 58
Long-term depression 0.001178836 48 46
Serotonergic synapse 0.001245646 81 51
TGF-beta signaling pathway 0.001498476 58 54
Pancreatic cancer 0.001536223 53 49
FoxO signaling pathway 0.001905724 98 59
ErbB signaling pathway 0.002223208 66 51
MAPK signaling pathway 0.002252012 183 66
Signaling pathways regulating
pluripotency of stem cells
0.002265893 102 61
Wnt signaling pathway 0.002265893 104 63
Melanoma 0.002526033 56 49
Long-term potentiation 0.002526033 54 52
Nicotine addiction 0.004752071 29 43
Prion diseases 0.006877062 20 36
Circadian rhythm 0.006877062 26 41
PI3K-Akt signaling pathway 0.006877062 235 70
Prostate cancer 0.006944825 67 57
Neurotrophin signaling pathway 0.008178726 88 58
Oxytocin signaling pathway 0.008178726 111 62
mTOR signaling pathway 0.00860707 48 54
Endocrine and other factor-regulated
calcium reabsorption
0.009616617 34 47
Renal cell carcinoma 0.009616617 52 47
Platelet activation 0.010946918 94 55
Adrenergic signaling in cardiomyocytes 0.010946918 102 60
Endocytosis 0.010946918 144 63
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Discussion
To our knowledge, this is the first study to establish a
potential global serum miRNA signature in OA patients
using a high-resolution microarray technology interro-
gating 2549 miRNAs. We identified a three-miRNA sig-
nature, including hsa-miR-140-3p, hsa-miR-671-3p, and
hsa-miR-33b-3p, which was downregulated in the serum
of OA patients compared to controls and in silico pre-
dicted to be involved in regulating metabolic factors.
Recent evidence points that circulating miRNAs could
derive from tissue injury [42] or adipose tissue depots
[43], it could thus be speculated that serum miRNAs in
OA could potentially have derived from cartilage degen-
eration, apoptosis, or inflammation, and miRNA expres-
sion profiling in OA serum could thus constitute a
disease fingerprint.
To date, limited studies have been conducted, mainly
using low-density arrays and qRT-PCR for the identifica-
tion of circulating miRNA expression profile in serum,
plasma or blood of OA patients, with inconsistent re-
sults among different studies. More specifically, Okuhara
et al., investigated the expression of hsa-miR-146a, hsa-
miR-155, hsa-miR-181a, and hsa-miR-223 by qRT-PCR
in peripheral blood mononuclear cells of OA patients
and healthy controls and correlated their expression to
disease progression [44]. In a subsequent study, the
expression of 380 miRNAs using TaqMan low density
arrays was evaluated in the plasma of patients with
primary osteoarthritis and controls and 12 miRNAs
(hsa-miR-16, hsa-miR-20b, hsa-miR-29c, hsa-miR-30b,
hsa-miR-93, hsa-miR-126, hsa-miR-146a, hsa-miR-184,
Table 2 Summary of 77 miRNAs that were found significant in ROC analysis in common annotated pathways (Continued)
KEGG pathway p value #genes #miRNAs
Non-small cell lung cancer 0.011911365 43 47
Cholinergic synapse 0.012031519 79 56
Glioma 0.012204133 47 48
cGMP-PKG signaling pathway 0.01268481 117 67
Endometrial cancer 0.01424854 40 54
Estrogen signaling pathway 0.01424854 70 55
Choline metabolism in cancer 0.01424854 73 62
Chronic myeloid leukemia 0.01491545 54 52
Calcium signaling pathway 0.01491545 126 59
GnRH signaling pathway 0.015627113 68 51
Gap junction 0.015668053 62 51
Amphetamine addiction 0.016450563 49 52
T cell receptor signaling pathway 0.018715138 76 52
Glycosaminoglycan biosynthesis-
heparan sulfate/heparin
0.021909011 18 29
Dorso-ventral axis formation 0.021911194 23 40
ECM-receptor interaction 0.02302011 59 49
Focal adhesion 0.023875829 143 62
Regulation of actin cytoskeleton 0.027660198 149 66
Sphingolipid signaling pathway 0.035172679 80 57
Small cell lung cancer 0.046657913 62 45
Cocaine addiction 0.046657913 36 49
Ubiquitin-mediated proteolysis 0.046657913 98 61
Fig. 4 Venn diagram of common target genes between miR-140-3p,
miR-33b-3p and miR-671-3p
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hsa-miR-186, hsa-miR-195, hsa-miR-345, and hsa-miR-
885) were identified being over-expressed in OA patients
[28]. A more recent study by Beyer et al. [27] identified
let-7e in the serum of a large population-based cohort of
OA patients necessitating arthroplasty as a potential pre-
dictor for severe knee or hip osteoarthritis; however, its
expression was not confirmed in OA articular cartilage
samples. The inability among the published studies to
reveal consistent differentially expressed circulating miR-
NAs in OA could be attributed to differences in the
study design, as selection of patients, disease status, and
differences in ethnicity [45], and to different platforms
and bioinformatics tools used in each study.
In the current setting among the 2549 miRNAs
screened using a high-density microarray platform, we
identified 279 miRNAs of which 205 upregulated and 74
downregulated, that were differentially expressed in serum
between OA patients and healthy individuals. Hierarchical
clustering analysis (HCA) using the miRNA signatures
failed to demonstrate clear differences between OA and
control serum samples. This inability of HCA might be
due to the small sample size or to other technical issues,
as the low dynamic range of miRNA microarrays com-
pared to qRT-PCR to accurately identify fold-changes for
miRNAs present in both high and low abundance [46].
In order to evaluate the diagnostic role of the circulat-
ing miRNAs in OA serum, we established ROC curves
using a strict filtering approach. We determined 77 miR-
NAs that showed significant sensitivity and specificity
with area AUC values > 0.8, suggesting those miRNAs as
potential OA biomarkers. Many of these miRNAs have
yet unknown roles that remain to be revealed. To evalu-
ate the biological information provided by the 77 miR-
NAs through ROC analysis, we performed pathway
enrichment analysis, which revealed that their target
genes were commonly enriched in OA related pathways,
such as ECM-receptor interaction, mTOR, PI3K/Akt,
Wnt, TGF-β and adipocytokine signaling pathways, insu-
lin resistance, FoxO, autophagy, and fatty acid metabol-
ism (Table 2).
We, next, validated with qRT-PCR, which offers high
accuracy, sensitivity, and dynamic range [46] the expres-
sion levels of 7 selected out of the 77 DE miRNAs,
which were among the top 20 up- or downregulated in
the microarray screening, namely, hsa-miR-33b-3p, hsa-
miR-4284, hsa-miR-663a, hsa-miR-150-5p, hsa-miR-
1233-3p, hsa-miR-140-3p, and hsa-miR-671-3p, in serum
and in OA and healthy articular cartilage samples. We
found that three miRNAs, hsa-miR-140-3p, hsa-miR-
671-3p, and hsa-miR-33b-3p, were significantly down-
regulated in the serum of OA patients compared to
controls, and in addition, hsa-miR-140-3p and hsa-miR-
671-3p were also significantly downregulated in OA com-
pared to healthy articular cartilage (Figs. 3a, b and 6).
Hsa-miR-140 plays an important role in cartilage
homeostasis and chondrogenesis [47–49] and has been
previously reported with differential expression in OA
cartilage [44, 50] but not in serum. Recently, it was
Fig. 5 Venn diagram of common signaling pathways between miR-140-3p, miR-33b-3p and miR-671-3p
Ntoumou et al. Clinical Epigenetics  (2017) 9:127 Page 10 of 15
Table 3 Disease annotation of participation of selected miRNAs among others in arthritis, joint diseases, and rheumatic diseases
Index UserID Value Gene symbol Gene name EntrezGene Ensembl
Database: disease Name: Carcinoma, Small Cell ID:DB_ID:PA446661
C = 278; O = 3; E = 0.21; R = 14.54; rawP = 0.0011; adjP = 0.0121
1 MIR185 NA MIR185 microRNA 185 406,961 NULL
2 MIR138-1 NA MIR138-1 microRNA 138-1 406,929 NULL
3 MIR200A NA MIR200A microRNA 200a 406,983 NULL
Database: disease Name: Lymphoma, Large-Cell, Diffuse ID:DB_ID:PA446313
C = 262; O = 2; E = 0.19; R = 10.29; rawP = 0.0162; adjP = 0.0307
1 MIR4488 NA MIR4488 microRNA 4488 100,616,470 NULL
2 MIR4492 NA MIR4492 microRNA 4492 100,616,376 NULL
Database: disease Name: Arthritis ID:DB_ID:PA443430
C = 302; O = 2; E = 0.22; R = 8.93; rawP = 0.0211; adjP = 0.0307
1 MIR140 NA MIR140 microRNA 140 406,932 NULL
2 MIR346 NA MIR346 microRNA 346 442,911 NULL
Database: disease Name: Neoplasms ID:DB_ID:PA445062
C = 854; O = 3; E = 0.63; R = 4.73; rawP = 0.0251; adjP = 0.0307
1 MIR185 NA MIR185 microRNA 185 406,961 NULL
2 MIR138-1 NA MIR138-1 microRNA 138-1 406,929 NULL
3 MIR200A NA MIR200A microRNA 200a 406,983 NULL
Database: disease Name: Hematologic Neoplasms ID:DB_ID:PA446827
C = 273; O = 2; E = 0.20; R = 9.87; rawP = 0.0175; adjP = 0.0307
1 MIR671 NA MIR671 microRNA 671 768,213 NULL
2 MIR758 NA MIR758 microRNA 758 768,212 NULL
Database: disease Name: Brain Neoplasms ID:DB_ID:PA443557
C = 198; O = 2; E = 0.15; R = 13.61; rawP = 0.0095; adjP = 0.0307
1 MIR326 NA MIR326 microRNA 326 442,900 NULL
2 MIR200A NA MIR200A microRNA 200a 406,983 NULL
Database: disease Name: Joint Diseases ID:DB_ID:PA444661
C = 266; O = 2; E = 0.20; R = 10.13; rawP = 0.0166; adjP = 0.0307
1 MIR140 NA MIR140 microRNA 140 406,932 NULL
2 MIR346 NA MIR346 microRNA 346 442,911 NULL
Database:disease Name: Rheumatic Diseases ID:DB_ID:PA445555
C = 295; O = 2; E = 0.22; R = 9.14; rawP = 0.0202; adjP = 0.0307
1 MIR140 NA MIR140 microRNA 140 406,932 NULL
2 MIR346 NA MIR346 microRNA 346 442,911 NULL
Database: disease Name: Hematologic Diseases ID:DB_ID:PA444395
C = 316; O = 2; E = 0.23; R = 8.53; rawP = 0.0230; adjP = 0.0307
1 MIR671 NA MIR671 microRNA 671 768,213 NULL
2 MIR150 NA MIR150 microRNA 150 406,942 NULL
Database: disease Name: Carcinoma ID:DB_ID:PA443610
C = 522; O = 2; E = 0.39; R = 5.16; rawP = 0.0571; adjP = 0.0628
1 MIR138-1 NA MIR138-1 microRNA 138-1 406,929 NULL
2 MIR200A NA MIR200A microRNA 200a 406,983 NULL
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shown that miR-140 is required for adipogenesis [51]and
that decreased levels of miR-140 were found in the plasma
of patients with morbid obesity influencing TGFbR1 ex-
pression levels [51], suggesting a new role of miR-140 in
metabolic processes and obesity, main contributors in OA
development. Disease Association Annotation in our
study revealed that among the differentially expressed
miRNAs, hsa-miR-140-3p was involved in arthritic dis-
eases. Regarding hsa-miR-671-3p and hsa-miR-33b, there
are no reports on their involvement in OA pathogenesis.
Human miR-33 has two isoforms, has-miR-33a and has-
miR-33b, which share the same seed sequence, have the
same predicted targets, and are both regulating lipid and
cholesterol metabolism [19, 52]. Our group has
highlighted the role of hsa-miR-33a in regulating choles-
terol transport genes [53]. Recently, miR-33b was shown
to regulate adipocyte differentiation [54] and miR-33a dif-
ferent functions of macrophages having a role in develop-
ment and progress of atherosclerosis [55]. Regarding miR-
671, besides its role in cancer cell migration [56], it was
recently indicated that it regulates apoptotic genes such as
caspase 8, p38, Myc-associated factor X (MAX), and Ras
protein-specific guanine nucleotide releasing factor 1
(RASGRF1) in neurons of mice [56] and that it suppresses
macrophage-mediated inflammation in orbital fat-derived
stem cells by upregulating IL-IRA and TNFRII expressions
[57, 58] highlighting its potential role in apoptosis and in-
flammation, both processes involved in OA.
Target gene analysis of hsa-miR-140-3p, hsa-miR-33b-
3p, and hsa-miR-671-3p revealed that 28 genes were co-
targeted by at least two miRNAs. Among common target-
genes were insulin-like growth factor 1 receptor (IGF1R),
insulin receptor (InsR), transforming growth factor beta
receptor 1 (TGFβR1), cAMP responsive element binding
protein 5 (CREB5), nuclear factor kB (NFkB), and tumor
necrosis factor a (TNFa), genes enriched in inflammatory
and metabolic processes as revealed by pathway analysis
(Figs. 4 and 5). An interesting finding in the in silico pre-
diction analysis was that InsR and IGFR1 were common
targets of all three hsa-miR-140-3p, hsa-miR-33b-3p, and
hsa-miR-671. Insulin is mediating its effects by binding to
the specific high affinity insulin receptor (InsR), or with
lower affinity to the structural- and functionally related
insulin-like growth factor receptor (IGFR) [59]. Taking
into consideration that OA is a metabolic disease [6], that
insulin resistance plays a key role in the metabolic syn-
drome [3], and that recently a correlation was demon-
strated between radiographic OA severity and insulin
resistance [7], our in silico prediction analysis adds to the
above evidence, suggesting a possible role of insulin resist-
ance in OA. Along the same thought process, another in-
teresting finding in our study was that cAMP responsive
element binding protein 5 (CREB5), co-targeted by hsa-
miR-140-3p and hsa-miR-671-3p, was significantly
enriched in insulin secretion and TNF signaling pathways.
CREB5 is a primary regulator of adipogenesis, that is also
involved in regulating innate immune system, aging-
associated inflammation and glucose homeostasis [60, 61]
and under obese conditions promotes insulin resistance
by activating the transcriptional repressor ATF3 and by
downregulating the expression of adiponectin as well as
insulin-sensitive glucose transporter 4 (GLUT4) [62].
All above suggest that the in silico predictions in the
present study are highlighting the possible implication of
circulating hsa-miR-140-3p, hsa-miR-33b-3p, and hsa-
miR-671-3p as novel serum-based biomarkers for
Fig. 6 Diagram of relative miRNA expression levels by qRT-PCR in normal (n = 7) and osteoarthritic (OA) chondrocytes (n = 12). U6 was used for
normalization of the real-time PCR data. All miRNAs appeared to be downregulated with respect to control samples. Fold change has
been calculated as the log2 transformed ratio of the 2−ΔΔCt of OA samples over control samples (asterisks depict a significant difference
between the 2−ΔΔCt of OA samples and 2−ΔΔCt of control samples in cartilage tissues at the p < 0.05 level). Hsa-miR-140-3p, hsa-miR-671-3p, and
hsa-miR-150p were significantly downregulated in serum samples of OA patients compared to healthy individuals
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osteoarthritis prognosis and underlining their involve-
ment in the regulation of metabolic processes that con-
tribute to OA pathology. However, functional studies
need to be conducted to verify our bioinformatics ana-
lysis and to shed light on the metabolic pathways
through which the above miRNA signature leads to OA
onset and development. In addition, standardized proto-
cols for circulating miRNA isolation and analysis in lar-
ger cohorts of different ethnicities must be established
before their use in clinical practice.
Conclusions
A serum miRNA signature was established, for the first
time, using high-density resolution miR-arrays in OA
patients, and their deregulation was verified in articular
cartilage samples. We identified a three-miRNA signa-
ture, hsa-miR-140-3p, hsa-miR-671-3p, and hsa-miR-
33b-3p, in serum predicted to regulate metabolic pro-
cesses, which could serve as a potential biomarker for
the evaluation of OA risk and progression.
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